...
首页> 外文期刊>American journal of clinical dermatology >Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers.
【24h】

Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers.

机译:两种组合痤疮产品的潜在刺激性比较:一项针对健康志愿者的随机对照,受试者和评估者盲比较研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Two topical 1% clindamycin/5% benzoyl peroxide combination products (BenzaClin [Dermik Laboratories, Inc., Bridgewater, NJ, USA] and Duac [Stiefel Laboratories, Coral Gables, FL, USA]) are commonly used in the treatment of mild-to-moderate acne vulgaris. One adverse event reported with their use is local skin irritation. OBJECTIVE: The primary aim of this study was to compare the irritation potential of BenzaClin and Duac using a cumulative irritant patch test on healthy human skin. METHODS: A randomized controlled, subject- and evaluator-blinded design was used to compare the cumulative irritation potential of BenzaClin, Duac, a positive control (0.2% sodium laurilsulfate [SLS]), and a negative control (white petrolatum) in healthy volunteers at a single US research study center. Forty subjects were enrolled and 37 completed the study. Most subjects were women (83%) and Caucasian (68%), and the mean age was 47 years. The 21-day cumulative irritation patch test was used to measure the irritation potential of the products applied under occlusive conditions. Evaluation of dermal reactions to the four products was assessed visually using an ordinal scoring system at the time of removal of each patch. The four patches were applied once daily over 21 days, excluding Saturdays and Sundays, resulting in a total of 15 applications. The primary endpoint, determined prior to data collection, was mean cumulative irritation score at the end of the study on day 22. RESULTS: At the end of the study, the mean cumulative irritation scores were not significantly different between BenzaClin and Duac (1.39 vs 1.36, respectively; p = 0.668). Both BenzaClin and Duac were significantly more irritating than white petrolatum and significantly less irritating than SLS (both p < 0.001). Based on mean cumulative irritation score, BenzaClin and Duac were classified as moderately irritating, SLS as highly irritating, and white petrolatum as not irritating. CONCLUSION: BenzaClin and Duac show similar propensity to cause moderate irritation compared with SLS and white petrolatum when applied to the skin of healthy subjects under occlusive patch conditions.
机译:背景:两种局部用1%克林霉素/ 5%过氧化苯甲酰组合产品(BenzaClin [Dermik Laboratories,Inc.,Bridgewater,NJ,美国]和Duac [Stiefel Laboratories,Coral Gables,FL,USA])通常用于治疗轻度至中度寻常痤疮。据报道使用它们的一个不良事件是局部皮肤刺激。目的:本研究的主要目的是使用累积刺激性斑贴试验对健康的人类皮肤进行BenzaClin和Duac的刺激潜力比较。方法:采用随机对照,受试者和评估者双盲设计,比较健康志愿者中苯扎克林,Duac,阳性对照(0.2%月桂基硫酸钠[SLS])和阴性对照(白凡士林)的累积刺激潜力。在单一的美国研究学习中心。招募了40名受试者,其中37名完成了研究。大多数受试者为女性(83%)和白人(68%),平均年龄为47岁。使用21天累积刺激贴剂测试来测量在封闭条件下使用的产品的刺激潜力。在去除每个贴剂时,使用顺序评分系统目测评估对四种产品的皮肤反应。这四个补丁程序在21天之内每天应用一次,不包括周六和周日,因此总共有15个应用程序。在收集数据之前确定的主要终点是研究结束时第22天的平均累积刺激分数。结果:在研究结束时,BenzaClin和Duac之间的平均累积刺激分数没有显着差异(1.39 vs 1.36; p = 0.668)。 BenzaClin和Duac的刺激性均显着高于白色凡士林,而刺激性则显着低于SLS(均P <0.001)。根据平均累积刺激评分,将BenzaClin和Duac划为中度刺激,将SLS划为高度刺激,将白凡士林划为不刺激。结论:与SLS和白凡士林相比,将BenzaClin和Duac应用于健康受试者在闭塞性贴片条件下的皮肤时,具有中等程度的刺激倾向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号